131 related articles for article (PubMed ID: 16773328)
1. Ex vivo therapy of malignant melanomas transplanted into organotypic brain slice cultures using inhibitors of histone deacetylases.
Hölsken A; Eyüpoglu IY; Lueders M; Tränkle C; Dieckmann D; Buslei R; Hahnen E; Blümcke I; Siebzehnrübl FA
Acta Neuropathol; 2006 Aug; 112(2):205-15. PubMed ID: 16773328
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the in vitro and in vivo antitumor activity of histone deacetylase inhibitors for the therapy of retinoblastoma.
Dalgard CL; Van Quill KR; O'Brien JM
Clin Cancer Res; 2008 May; 14(10):3113-23. PubMed ID: 18483379
[TBL] [Abstract][Full Text] [Related]
3. Multiple Molecular pathways explain the anti-proliferative effect of valproic acid on prostate cancer cells in vitro and in vivo.
Shabbeer S; Kortenhorst MS; Kachhap S; Galloway N; Rodriguez R; Carducci MA
Prostate; 2007 Jul; 67(10):1099-110. PubMed ID: 17477369
[TBL] [Abstract][Full Text] [Related]
4. Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.
Höti N; Chowdhury W; Hsieh JT; Sachs MD; Lupold SE; Rodriguez R
Mol Ther; 2006 Dec; 14(6):768-78. PubMed ID: 16990052
[TBL] [Abstract][Full Text] [Related]
5. Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor: effects on gene expression and growth of glioma cells in vitro and in vivo.
Yin D; Ong JM; Hu J; Desmond JC; Kawamata N; Konda BM; Black KL; Koeffler HP
Clin Cancer Res; 2007 Feb; 13(3):1045-52. PubMed ID: 17289901
[TBL] [Abstract][Full Text] [Related]
6. Multicenter phase II trial of the histone deacetylase inhibitor pyridylmethyl-N-{4-[(2-aminophenyl)-carbamoyl]-benzyl}-carbamate in pretreated metastatic melanoma.
Hauschild A; Trefzer U; Garbe C; Kaehler KC; Ugurel S; Kiecker F; Eigentler T; Krissel H; Schott A; Schadendorf D
Melanoma Res; 2008 Aug; 18(4):274-8. PubMed ID: 18626312
[TBL] [Abstract][Full Text] [Related]
7. MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors.
Jaboin J; Wild J; Hamidi H; Khanna C; Kim CJ; Robey R; Bates SE; Thiele CJ
Cancer Res; 2002 Nov; 62(21):6108-15. PubMed ID: 12414635
[TBL] [Abstract][Full Text] [Related]
8. Sulfonamide anilides, a novel class of histone deacetylase inhibitors, are antiproliferative against human tumors.
Fournel M; Trachy-Bourget MC; Yan PT; Kalita A; Bonfils C; Beaulieu C; Frechette S; Leit S; Abou-Khalil E; Woo SH; Delorme D; MacLeod AR; Besterman JM; Li Z
Cancer Res; 2002 Aug; 62(15):4325-30. PubMed ID: 12154036
[TBL] [Abstract][Full Text] [Related]
9. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy.
Hahnen E; Eyüpoglu IY; Brichta L; Haastert K; Tränkle C; Siebzehnrübl FA; Riessland M; Hölker I; Claus P; Romstöck J; Buslei R; Wirth B; Blümcke I
J Neurochem; 2006 Jul; 98(1):193-202. PubMed ID: 16805808
[TBL] [Abstract][Full Text] [Related]
10. Antitumor activity of the histone deacetylase inhibitor MS-275 in prostate cancer models.
Qian DZ; Wei YF; Wang X; Kato Y; Cheng L; Pili R
Prostate; 2007 Aug; 67(11):1182-93. PubMed ID: 17520666
[TBL] [Abstract][Full Text] [Related]
11. A novel histone deacetylase inhibitor, CG0006, induces cell death through both extrinsic and intrinsic apoptotic pathways.
Hwang JJ; Kim YS; Kim MJ; Jang S; Lee JH; Choi J; Ro S; Hyun YL; Lee JS; Kim CS
Anticancer Drugs; 2009 Oct; 20(9):815-21. PubMed ID: 19644355
[TBL] [Abstract][Full Text] [Related]
12. The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo.
Tumber A; Collins LS; Petersen KD; Thougaard A; Christiansen SJ; Dejligbjerg M; Jensen PB; Sehested M; Ritchie JW
Cancer Chemother Pharmacol; 2007 Jul; 60(2):275-83. PubMed ID: 17124594
[TBL] [Abstract][Full Text] [Related]
13. Antiproliferative and proapoptotic effects of histone deacetylase inhibitors on gastrointestinal neuroendocrine tumor cells.
Baradari V; Huether A; Höpfner M; Schuppan D; Scherübl H
Endocr Relat Cancer; 2006 Dec; 13(4):1237-50. PubMed ID: 17158768
[TBL] [Abstract][Full Text] [Related]
14. SAR and biological evaluation of analogues of a small molecule histone deacetylase inhibitor N-(2-aminophenyl)-4-((4-(pyridin-3-yl)pyrimidin-2-ylamino)methyl)benzamide (MGCD0103).
Raeppel S; Zhou N; Gaudette F; Leit S; Paquin I; Larouche G; Moradei O; Fréchette S; Isakovic L; Delorme D; Fournel M; Kalita A; Lu A; Trachy-Bourget MC; Yan PT; Liu J; Rahil J; Wang J; Besterman JM; Murakami K; Li Z; Vaisburg A
Bioorg Med Chem Lett; 2009 Feb; 19(3):644-9. PubMed ID: 19114304
[TBL] [Abstract][Full Text] [Related]
15. In vivo imaging of retinoic acid receptor beta2 transcriptional activation by the histone deacetylase inhibitor MS-275 in retinoid-resistant prostate cancer cells.
Qian DZ; Ren M; Wei Y; Wang X; van de Geijn F; Rasmussen C; Nakanishi O; Sacchi N; Pili R
Prostate; 2005 Jun; 64(1):20-8. PubMed ID: 15651062
[TBL] [Abstract][Full Text] [Related]
16. HDAC inhibitors induce apoptosis in glucocorticoid-resistant acute lymphatic leukemia cells despite a switch from the extrinsic to the intrinsic death pathway.
Tsapis M; Lieb M; Manzo F; Shankaranarayanan P; Herbrecht R; Lutz P; Gronemeyer H
Int J Biochem Cell Biol; 2007; 39(7-8):1500-9. PubMed ID: 17499001
[TBL] [Abstract][Full Text] [Related]
17. CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.
Gensert JM; Baranova OV; Weinstein DE; Ratan RR
Neurobiol Dis; 2007 Jun; 26(3):671-80. PubMed ID: 17481908
[TBL] [Abstract][Full Text] [Related]
18. Synergistic in vivo antitumor effect of the histone deacetylase inhibitor MS-275 in combination with interleukin 2 in a murine model of renal cell carcinoma.
Kato Y; Yoshimura K; Shin T; Verheul H; Hammers H; Sanni TB; Salumbides BC; Van Erp K; Schulick R; Pili R
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4538-46. PubMed ID: 17671140
[TBL] [Abstract][Full Text] [Related]
19. Anti-tumor activity of N-hydroxy-7-(2-naphthylthio) heptanomide, a novel histone deacetylase inhibitor.
Kim DH; Lee J; Kim KN; Kim HJ; Jeung HC; Chung HC; Kwon HJ
Biochem Biophys Res Commun; 2007 Apr; 356(1):233-8. PubMed ID: 17353008
[TBL] [Abstract][Full Text] [Related]
20. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
